Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
Unlocking Nordic Healthcare Data with Medaffcon
The Nordics offer a unique environment for healthcare research and data utilisation. With Medaffcon, international partners – such as pharmaceutical companies – can make use of this environment effectively, systematically, and successfully.
The Nordic countries are known for their high-quality healthcare, systematic registries, and strong research infrastructure. Pharma and technology companies can greatly benefit from these, but navigating the national processes, from data access applications to analysis, requires deep local expertise and an understanding of each country’s health-data infrastructure.
Access to the right data is critical for successful research and this is Medaffcon’s core expertise.
Medaffcon knows the Nordics and the data
Medaffcon has strong Real-World Evidence (RWE) expertise, established processes for data collection, and specialists based in both Finland and Sweden. Medaffcon also has deep knowledge of each Nordic country’s ethical practices, legal frameworks, and research infrastructures.
Medaffcon’s Scientific Advisor, Johan Rehnberg, is involved in multiple projects across the Nordic countries. These projects are always carried out in collaboration with experts from respective country. According to Rehnberg, Medaffcon specialists know how to design and execute data collection processes that account for the specific features of each country, such as data accessibility, registry structures, and approval procedures.
“A Nordic approach to data collection carried out through Medaffcon saves clients’ resources, reduces duplicate work, and accelerates processes. Clients don’t need to establish separate projects in each country, as Medaffcon provides a Nordic approach to collecting and analysing information from multiple countries,” Rehnberg explains.
Generalisability and transferability: applying evidence beyond its original setting
High-quality data collected in one Nordic country can often provide valuable insights for the entire region. However, combining data from two or more countries further strengthens the generalisability of results. This supports research and development in many ways, since healthcare systems, patient profiles, and disease prevalence are partly similar across the region.
From Local Findings to Nordic Impact
- Stronger evidence with broader data – While findings from one Nordic country may be transferable, including data from two or more countries increases robustness and makes evidence more representative for the entire Nordic region.
- Larger and richer samples – Each Nordic country has long-standing, national registries and well-established research infrastructures. Collecting and analysing data from multiple countries allows for larger study populations, making it possible to investigate rare diseases and specific patient subgroups..
- Supporting policy and development – When drug development and Health Technology Assessment (HTA) processes require broader evidence, Nordic real-world data strengthens the overall picture and supports decision-making across the Nordics.
